FEIBA

This brand name is authorized in Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug FEIBA contains a combination of these active pharmaceutical ingredients (APIs):

1	Factor VIII inhibitor bypass activity UNII CS849DUN3M - ANTI-INHIBITOR COAGULANT COMPLEX
	Read more about Factor VIII inhibitor bypass activity
2	Coagulation factor II UNII 25ADE2236L - THROMBIN
	Read more about Thrombin
3	Coagulation factor IX UNII 6U90Y1795T - COAGULATION FACTOR IX HUMAN
	Factor IX is a single chain glycoprotein with a molecular mass of about 68,000 Dalton. It is a vitamin-K dependent coagulation factor and it is synthesised in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway and by the factor VII/tissue factor complex in the extrinsic pathway. Activated factor IX, in combination with activated factor VIII, activates factor X.
	Read more about Coagulation factor IX
4	Coagulation factor X UNII 0P94UQE6SY - COAGULATION FACTOR X HUMAN
	Coagulation factor X is derived from human plasma and used as a replacement for the naturally existing coagulation factor X in patients with hereditary factor X deficiency.
	Read more about Coagulation factor X
5	Coagulation factor VII UNII 4156XVB4QD - COAGULATION FACTOR VII HUMAN
	Read more about Coagulation factor VII

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FEIBA Powder and solvent for solution for infusion	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BD03	Factor VIII inhibitor bypassing activity	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501121010036917, 501121010037017, 501121010037117, 501121010037217, 501121010037317, 501121010037417, 501121010037517, 501121010037617
CA	Health Products and Food Branch	02202581, 02353903
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29195-03-10
EE	Ravimiamet	1021329, 1021330, 1680410, 1680421, 1680432, 1743397
ES	Centro de información online de medicamentos de la AEMPS	80119
FI	Lääkealan turvallisuus- ja kehittämiskeskus	186799
FR	Base de données publique des médicaments	67621498
GB	Medicines & Healthcare Products Regulatory Agency	174903, 393851, 393854, 95079
HK	Department of Health Drug Office	56854, 57891
HR	Agencija za lijekove i medicinske proizvode	HR-H-348186000, HR-H-682573334
IL	מִשְׂרַד הַבְּרִיאוּת	6807
JP	医薬品医療機器総合機構	6343414X2058
LT	Valstybinė vaistų kontrolės tarnyba	1000755, 1007752, 1071195, 1072764, 1080040, 1080041, 1085816, 1085817
MT	Medicines Authority	MA1047/00201, MA1047/00202
NL	Z-Index G-Standaard	14281244
NL	Z-Index G-Standaard, PRK	62464, 62472
NZ	Medicines and Medical Devices Safety Authority	10039, 10040, 14564
PL	Rejestru Produktów Leczniczych	100023736, 100195220, 100427356
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62498001, W62498002, W62499001, W62499002, W62499003, W62499004, W62499005
SG	Health Sciences Authority	10886P, 10889P
TN	Direction de la Pharmacie et du Médicament	10623041H
TR	İlaç ve Tıbbi Cihaz Kurumu	8681429550073, 8681429550363
ZA	Health Products Regulatory Authority	T/30.3/597, T/30.3/598